Paul Horstmeier - 07 Jun 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Issuer symbol: HCAT
Transactions as of: 07 Jun 2021
Transactions value $: -$382,195
Form type: 4
Filing time: 09 Jun 2021, 21:17:06 UTC
Previous filing: 03 Jun 2021
Next filing: 08 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$96,037	+6,063	+5.24%	$15.84	121,764	07 Jun 2021	Direct
transaction	HCAT	Common Stock	Sale	-$64,634	-1,202	-0.99%	$53.77^*	120,562	07 Jun 2021	Direct	F1, F2
transaction	HCAT	Common Stock	Sale	-$16,395	-300	-0.25%	$54.65^*	120,262	07 Jun 2021	Direct	F1, F3
transaction	HCAT	Common Stock	Sale	-$252,304	-4,516	-3.76%	$55.87^*	115,746	07 Jun 2021	Direct	F1, F4
transaction	HCAT	Common Stock	Sale	-$2,536	-45	-0.04%	$56.37^*	115,701	07 Jun 2021	Direct	F1, F5
transaction	HCAT	Common Stock	Sale	-$29,284	-545	-0.47%	$53.73^*	115,156	07 Jun 2021	Direct	F1, F6
transaction	HCAT	Common Stock	Sale	-$10,951	-200	-0.17%	$54.76^*	114,956	07 Jun 2021	Direct	F1, F7
transaction	HCAT	Common Stock	Sale	-$102,126	-1,827	-1.59%	$55.9^*	113,129	07 Jun 2021	Direct	F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-6,063	-5.92%	$0	96,404	07 Jun 2021	Common Stock	6,063	$15.84	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F2	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $53.23 to $54.10, inclusive.
F3	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $54.23 to $54.95, inclusive.
F4	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $55.30 to $56.27, inclusive.
F5	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $56.36 to $56.40, inclusive.
F6	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $53.25 to $54.03, inclusive.
F7	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $54.27 to $55.24, inclusive.
F8	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $55.43 to $56.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) through (8).
F9	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.